ERBB2 and breast cancer: High levels of tumor-infiltrating lymphocytes that comprise CD4+ helper and CD8+ cytotoxic T cells correlate with a better prognosis in patients with basal-like and HER2-positive breast cancer 8-10, suggesting that immune activation in modulating the TME favors host antitumor immunity, which points to a promising modality for fighting breast cancer.